Private Companies 12

USA

June 19, 2018: LifeScience Logistics, LLC: Universal flu vaccine biotech seeks Big Pharma partnership for phase 3 testing: CEO

NEWS BITES - PRIVATE COMPANIES

Universal flu vaccine biotech seeks Big Pharma partnership for phase 3 testing: CEO

After reporting phase 2b results for FLU-v, SEEK Group CEO Gregory Stoloff said the program is ready for phase 3.

Source: Fierce Pharma

Universal flu vaccine biotech seeks Big Pharma partnership for phase 3 testing: CEO

INDEX

SECTION 1 LIFESCIENCE LOGISTICS, LLC PROFILE

SECTION 2 PRESS RELEASES: 2018

SECTION 1 LIFESCIENCE LOGISTICS, LLC PROFILE

1.1 ACTIVITIES

LifeScience Logistics, LLC provides healthcare supply chain solutions supply chain solutions. It offers warehousing services, such as storage and distribution of frozen, refrigerated, and controlled ambient products; and distribution services, including call center, Web order entry, pricing campaigns, charge backs, invoicing, Medicare and Medicaid administration, and accounts receivable services. The company also provides multimodal transportation services, such as international, domestic, cold chain, express/expedite, charter, next flight out, FTL/LTL, ocean, small package, and traditional air freight solutions; and outsourced business solutions, such as integrated Web based applications. It serves clients ranging from pharmaceutical companies to small startups, and traditional to direct channels; med device, biotech/biological, vaccines, and blood/plasma companies; and commercial and government sectors in the United States and internationally. The company was founded in 2006 and is based in Dallas, Texas with facilities in DFW Airport, Texas; Union City, Georgia; Columbia, Maryland; and Brownsburg, Indiana.

1.2 SUMMARY

PermID: 5035541026

Website: http://www.lslog.com

Industry: Healthcare Services

SECTION 2 PRESS RELEASES: 2018

June 18: LifeScience Logistics, LLC: Corporate responsibility investor group touts support of first-year resolutions over executive pay, drug pricing

Corporate responsibility investor group touts support of first-year resolutions over executive pay, drug pricing Investors at five drugmakers supported resolutions asking for more info about the link between drug prices and executive pay, but the tally didn't pass 30% at any of the companies.

Source: Fierce Pharma

Corporate responsibility investor group touts support of first-year resolutions over executive pay, drug pricing

Source: Company Website

June 13: LifeScience Logistics, LLC: Unofficial party at BIO featured dancers plastered with company logos, outraging leadership

Unofficial party at BIO featured dancers plastered with company logos, outraging leadership During the BIO International Convention in Boston last week, an unaffiliated party featured topless dancers and models painted with the logos of investment firms and biotech companies sponsoring the event, incensing the chairman of the trade group to the point of reconsidering their memberships in the organization.

Source: FierceMedicalDevices News

Unofficial party at BIO featured dancers plastered with company logos, outraging leadership

Source: Company Website

June 08: LifeScience Logistics, LLC: Alder brings on Juno executive as CEO to prep for its migraine launch

Alder brings on Juno executive as CEO to prep for its migraine launch Alder BioPharmaceuticals poached Juno Therapeutics' chief commercial officer to serve as president and CEO, adding operational expertise as it looks to submit its lead migraine treatment for the company's first FDA approval.

Source: Company Website

June 08: LifeScience Logistics, LLC: Pfizer wins appeal of Pound84M fine in U.K. over 2,600% price hike

Pfizer wins appeal of Pound84M fine in U.K. over 2,600% price hike After U.K. antitrust authorities smacked Pfizer with a record fine over a 2,600% price hike, the drugmaker won an appeal.

Source: Company Website

June 06: LifeScience Logistics, LLC: CEO: Win or lose on Ampyra patents, Acorda reps are safe with Parkinson's prospect

CEO: Win or lose on Ampyra patents, Acorda reps are safe with Parkinson's prospect

The threat of generics often means layoffs, and in the case of Acorda's Ampyra, that's been true. But even if the company loses its upcoming appeal on the multiple sclerosis drug's patents, its sales force won't have to worry, CEO Ron Cohen says.

Source: Company Website

May 17: LifeScience Logistics, LLC: Allergan's besieged Restasis patents get smacked again, this time in retailer antitrust suit

Allergan's besieged Restasis patents get smacked again, this time in retailer antitrust suit Allergan has already faced heaps of scrutiny for its strategies to protect blockbuster eye drug Restasis from generic competition, but it'll have to defend itself against a new group of plaintiffs now that four retail pharmacies have launched a lawsuit.

Source: Company Website

May 14: LifeScience Logistics, LLC: TP brings on Adverum's ex-CMO following launch of first-in-human study

TP brings on Adverum's ex-CMO following launch of first-in-human study Following a short stint at Adverum Biotechnologies, Athena Countouriotis, M.D., has joined TP Therapeutics as executive VP and chief medical officer, as the company prepares to unveil first-in-human study data for its lead cancer therapy and expand its pipeline.

Source: Company Website

May 09: LifeScience Logistics, LLC: Gilead shelved safer HIV drugs for years to protect its TDF monopoly, another lawsuit says

Gilead shelved safer HIV drugs for years to protect its TDF monopoly, another lawsuit says

Gilead Sciences is no stranger to furious patients and advocates claiming the company puts shareholder interests over their own. Now, two patients allege that the drugmaker shelved better and safer HIV treatments to keep sales of its older drugs coming, only to push the newer ones later.

Source: Fierce Pharma

Gilead shelved safer HIV drugs for years to protect its TDF monopoly, another lawsuit says

Source: Company Website

May 04: LifeScience Logistics, LLC: Patent fights jump in 2017 as Eli Lilly, Pfizer, Sanofi and more sue to protect their meds

Patent fights jump in 2017 as Eli Lilly, Pfizer, Sanofi and more sue to protect their meds In the ever-raging war between generic drugmakers and branded pharma, patent litigation is a standard-issue weapon. It's a high-stakes business as generics makers aim to grow their sales by rolling out copies of blockbuster drugs-and branded drugmakers seek to protect the billions in sales at risk.

Source: Company Website

May 02: LifeScience Logistics, LLC: Bristol-Myers Squibb and Flatiron to collaborate on real-world data standards for regulatory decisions

Bristol-Myers Squibb and Flatiron to collaborate on real-world data standards for regulatory decisions Bristol-Myers Squibb and Flatiron Health expanded their relationship with a new three-year agreement, and plan to form a joint scientific advisory board focused on using real-world evidence in regulatory submissions. Source: FierceMedicalDevices News Bristol-Myers Squibb and Flatiron to collaborate on real-world data standards for regulatory decisions

Source: Company Website

PermID: 5035541026

Created by www.buysellsignals.com for News Bites Finance